- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03763565
Effectiveness of HPV Vaccine in Thai Adult Women
Effectiveness of HPV Vaccine Among Women Age Equal or More Than 20 Years
- Background: The majority of the burden of HPV-related cervical cancer is in developing countries while most of the effectiveness reports of HPV vaccination are currently coming from developed countries. Also, currently many adult women are left without either HPV vaccination or cervical cancer screening. Effectiveness data of currently available HPV vaccines among adult women in developing countries are needed for women and healthcare workers and policy makers to best protect women from cervical cancer.
Primary Study Objective:
- To determine the effectiveness bivalent and quadrivalent HPV vaccines in reduction of cervical dysplasia (Low-grade Squamous Intraepithelial Lesion or worse; LSIL+) attributable to HPV types 16 or 18 after at least 5 years of vaccination among Thai women vaccinated at their ages 20-45 years with at least one dose of the HPV vaccine
Secondary Study Objectives:
- To measure the effectiveness of currently available bivalent and quadrivalent HPV vaccines in reducing the prevalence of HPV 16 or 18
- To measure the effectiveness of HPV vaccines in reducing any abnormal Pap smear result (ASC-US+)
- To compare the effectiveness of HPV vaccines according to the number of doses immunized
- To find out risk factor(s) for HPV 16 or 18-related cervical dysplasia in this cohort
- To assess the prevalence of other high-risk HPV types in vaccinated and non-vaccinated group
- To determine direct and/or indirect cost of HPV vaccination
- The hypothesis to be tested: At least one dose of vaccination with bi- or quadri-valent HPV vaccine will reduce the prevalence of LSIL+ attributable to HPV 16/18 by 80% after at least 5 years of vaccination.
- Materials and Methods: This study will be a retrospective matched cohort study. Data is to be collected either by from samples for Pap and HPV test and/or HPV 16/18 genotyping of the recruited participants, or from existing medical records. HPV vaccinated women at their ages 20-45 years (vaccinated group) and women received Pap smear at their ages 20-45 years without vaccination (control group) will be included in the study. Pap smear and HPV test and/or HPV 16/18 typing result of 2 groups will be compared after ≥ 5 years of vaccination or baseline Pap smear. Those who don't have Pap smear results ≥ 5 years after vaccination or ≥ 5 years after the baseline Pap smear will be offered for a Pap smear and HPV 16/18 typing
Study Overview
Status
Intervention / Treatment
Study Type
Enrollment (Actual)
Contacts and Locations
Study Contact
- Name: Punnee Pitisuttithum
- Phone Number: 6626435599
- Email: punnee.pit@mahidol.ac.th
Study Contact Backup
- Name: GA YOUNG LEE
- Phone Number: 66945525330
- Email: ga.young.lydia@gmail.com
Study Locations
-
-
-
Bangkok, Thailand, 10330
- King Chulalongkorn Memorial Hospital
-
Bangkok, Thailand, 10700
- Siriraj Hospital, Mahidol University
-
Bangkok, Thailand, 10400
- Vaccine Trial Centre, Faculty of Tropical Medicine, Mahidol University,
-
Bangkok, Thailand, 10110
- Bumrungrad International Hospital
-
Bangkok, Thailand, 10400
- National Cancer Institute, Thailand
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Sampling Method
Study Population
Vaccinated group: Thai women who received at least one dose of HPV vaccination, either by bivalent or quadrivalent HPV vaccine when they were 20-45 years old at least 5 years ago from the current enrollment time
Control group: Women who did not receive any HPV vaccination, but received Pap smear result (conventional or liquid-based) when they were 20-45 years at least 5 years ago from the current enrollment time
Description
Inclusion Criteria
(vaccinated group)
- Thai women aged 20-45 years at the time of HPV vaccination
- Received at least 1 dose of bivalent or quadrivalent HPV vaccine at least 5 years ago
- Willing to provide written informed consent and receive Pap smear & HPV genotyping (only for those who need specimen collection for cervical cytology and HPV genotyping result)
(control group)
- Thai women without history of HPV vaccination
- Received Pap smear result at their ages 20-45 years at least 5 years ago
- Willing to provide written informed consent and receive Pap smear & HPV genotyping (only for those who need specimen collection for cervical cytology and HPV genotyping result)
Exclusion Criteria:
- Known pregnancy
- History of hysterectomy or excisional treatment of the cervix
- Known increased risk of bleeding
- Not willing to provide written informed consent
Study Plan
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Vaccinated group
Thai women who received at least one dose HPV vaccination at least 5 years ago, either by Bivalent or Quadrivalent HPV vaccines when they were 20-45 years old
|
Vaccination with at least one dose of Bivalent or Quadrivalent HPV vaccines at least 5 years ago at the ages of 20-45 years
|
Control group
Thai women who did not receive HPV vaccination, either by bivalent or quadrivalent HPV vaccine but have received Pap smear at their ages 20-45 years at least 5 years ago from the current enrollment time
|
Thai women who did not receive HPV vaccination, either by bivalent or quadrivalent HPV vaccine but have received Pap smear at their ages 20-45 years at least 5 years ago from the current enrollment time
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Occurrence of Low-grade squamous intraepithelial lesion or worse (LSIL+) associated with HPV 16 or 18
Time Frame: Sample collection in the project is single 1 day time for participants who received vaccination at least 5 years ago.
|
LSIL or worse, including Atypical Glandular Cells, High-grade squamous intraepithelial lesion, Cervical intraepithelial neoplasia (CIN) grade 1-3, and cervical cancer which are associated with either HPV 16 or 18
|
Sample collection in the project is single 1 day time for participants who received vaccination at least 5 years ago.
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Cost-effectiveness of bivalent and quadrivalent HPV vaccination
Time Frame: Interview for direct and indirect cost survey will be single 1 day time for a participant.
|
Direct and and indirect cost survey interview associated with HPV vaccination and its cost-effectiveness
|
Interview for direct and indirect cost survey will be single 1 day time for a participant.
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Study Chair: Punnee Pitisuttithum, Mahidol University
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- HPV 021
- 2561.1/13 (Other Grant/Funding Number: National Vaccine Institute, Thailand)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Uterine Cervical Dysplasia
-
University of Mississippi Medical CenterNot yet recruitingCervical Dysplasia, Uterine | Vaginal Dysplasia | Vulvar Dysplasia
-
Sunnybrook Health Sciences CentreCompleted
-
H. Lee Moffitt Cancer Center and Research InstituteJames and Esther King Biomedical Research ProgramRecruitingSmoking Cessation | Cervical Cancer | High Grade Cervical DysplasiaUnited States
-
University of AarhusNot yet recruitingCervical Cancer
-
NHS Greater Glasgow and ClydeUnknownCervical Carcinoma | Cervical Dysplasia
-
William Marsh Rice UniversityM.D. Anderson Cancer Center; Albert Einstein College of Medicine; The Cleveland... and other collaboratorsCompleted
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Terminated
-
Ruhr University of BochumCompletedUterine Cervical DysplasiaGermany
-
Sarah HufCompletedCervical Carcinoma | Cervical DysplasiaUnited Kingdom
-
Ruhr University of BochumRecruiting
Clinical Trials on Bivalent or Quadrivalent HPV vaccines
-
Sun Yat-sen UniversityRecruitingPremature Ovarian Failure | Menstrual DisorderChina
-
Xiamen UniversityXiamen Innovax Biotech Co., Ltd; Beijing Wantai Biological Pharmacy Enterprise...Active, not recruitingCervical Cancer | Cervical Intraepithelial Neoplasia | Condylomata AcuminataChina
-
National Cancer Institute (NCI)Active, not recruitingHuman Papillomavirus-Related Cervical CarcinomaCosta Rica
-
Jun ZhangXiamen Innovax Biotech Co., Ltd; Beijing Wantai Biological Pharmacy Enterprise...CompletedCervical Cancer | Cervical Intraepithelial Neoplasia | Vaginal Intraepithelial Neoplasia | Vulvar Intraepithelial Neoplasia | Persistent InfectionChina
-
Jun ZhangXiamen Innovax Biotech Co., Ltd; Beijing Wantai Biological Pharmacy Enterprise...CompletedA Bridging Study of a Recombinant Human Papillomavirus 16/18 Bivalent Vaccine in Preadolescent GirlsCervical Cancer | Cervical Intraepithelial Neoplasia | Vaginal Intraepithelial Neoplasia | Vulvar Intraepithelial Neoplasia | Persistent InfectionChina
-
London School of Hygiene and Tropical MedicineNational Cancer Institute (NCI); Karolinska Institutet; Institut Català d'Oncologia and other collaboratorsActive, not recruitingHuman Papilloma VirusTanzania
-
University of AarhusAarhus University HospitalCompletedHIV | Human PapillomavirusDenmark
-
Emory UniversityNational Institute of Allergy and Infectious Diseases (NIAID)Completed
-
Southern California Institute for Research and...Merck Sharp & Dohme LLCUnknownHIV Infections | Anal CancerUnited States
-
University of PretoriaUniversity of StellenboschActive, not recruiting